Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Net Income (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Net Income for 9 consecutive years, with -$60.8 million as the latest value for Q1 2026.

  • For Q1 2026, Net Income changed 0.14% year-over-year to -$60.8 million; the TTM value through Mar 2026 reached -$225.7 million, down 856.59%, while the annual FY2025 figure was -$225.7 million, 2226.02% down from the prior year.
  • Net Income hit -$60.8 million in Q1 2026 for Bicycle Therapeutics, down from -$26.8 million in the prior quarter.
  • Across five years, Net Income topped out at $127.8 million in Q4 2024 and bottomed at -$79.0 million in Q2 2025.
  • Average Net Income over 5 years is -$33.8 million, with a median of -$39.8 million recorded in 2024.
  • Year-over-year, Net Income soared 341.5% in 2024 and then tumbled 129.1% in 2025.
  • Bicycle Therapeutics' Net Income stood at -$32.0 million in 2022, then plummeted by 65.19% to -$52.9 million in 2023, then skyrocketed by 341.5% to $127.8 million in 2024, then crashed by 121.01% to -$26.8 million in 2025, then plummeted by 126.54% to -$60.8 million in 2026.
  • According to Business Quant data, Net Income over the past three periods came in at -$60.8 million, -$26.8 million, and -$59.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.